Form 8-K - Current report:
SEC Accession No. 0001193125-24-231670
Filing Date
2024-10-03
Accepted
2024-10-03 08:31:28
Documents
14
Period of Report
2024-09-30
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d810672d8k.htm   iXBRL 8-K 33769
2 EX-4.1 d810672dex41.htm EX-4.1 69233
  Complete submission text file 0001193125-24-231670.txt   246358

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA etnb-20240930.xsd EX-101.SCH 2844
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE etnb-20240930_lab.xml EX-101.LAB 17994
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE etnb-20240930_pre.xml EX-101.PRE 11257
16 EXTRACTED XBRL INSTANCE DOCUMENT d810672d8k_htm.xml XML 3633
Mailing Address 142 SANSOME STREET SECOND FLOOR SAN FRANCISCO CA 94104
Business Address 142 SANSOME STREET SECOND FLOOR SAN FRANCISCO CA 94104 (415) 432-9270
89bio, Inc. (Filer) CIK: 0001785173 (see all company filings)

EIN.: 831114349 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39122 | Film No.: 241349981
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)